Vimta Labs Ltd. — Investor Relations & Filings
Vimta Labs Ltd. is a contract research and testing organization providing comprehensive scientific services across multiple sectors. The company specializes in analytical testing, clinical research, preclinical studies, and environmental monitoring. Its service portfolio includes pharmaceutical analysis, biopharmaceutical characterization, food safety testing, and diagnostic services. Vimta operates advanced laboratory facilities equipped to handle complex regulatory requirements, including compliance with global standards such as GLP, GCP, and ISO. The organization supports the life sciences, food, and electronics industries by offering specialized services like molecular biology, microbiology, and toxicology assessments. By integrating multi-disciplinary expertise, the company facilitates product development, quality control, and safety evaluations for a global clientele.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Copy of Newspaper Publication | 2026-05-07 | English | |
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-06 | English | |
| Change in Director(s) | 2026-05-06 | English | |
| Record Date | 2026-05-06 | English | |
| Outcome of Board Meeting | 2026-05-06 | English | |
| Dividend | 2026-05-06 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42965355 | Copy of Newspaper Publication | 2026-05-07 | English | ||
| 42163555 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-06 | English | ||
| 42166181 | Change in Director(s) | 2026-05-06 | English | ||
| 42171177 | Record Date | 2026-05-06 | English | ||
| 42171303 | Outcome of Board Meeting | 2026-05-06 | English | ||
| 42171271 | Dividend | 2026-05-06 | English | ||
| 42172778 | Press Release | 2026-05-06 | English | ||
| 42173852 | Investor Presentation | 2026-05-06 | English | ||
| 42174392 | Outcome of Board Meeting | 2026-05-06 | English | ||
| 42186784 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-04-29 | English | ||
| 42275161 | Board Meeting — Financial Results/Dividend | 2026-04-29 | English | ||
| 42275145 | Board Meeting — Board Meeting Intimation | 2026-04-29 | English | ||
| 42200408 | Copy of Newspaper Publication | 2026-04-28 | English | ||
| 42181696 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-08 | English | ||
| 42188955 | Trading Window | 2026-03-31 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Genprex, Inc.
Clinical-stage gene therapy company developing therapies fo…
|
GNPX | US | Professional, scientific and te… |
|
Genxone Spolka Akcyjna
A biotechnology company specializing in Next Generation Seq…
|
GX1 | PL | Professional, scientific and te… |
|
GeoVax Labs, Inc.
Clinical-stage biotech developing vaccines and therapies fo…
|
GOVX | US | Professional, scientific and te… |
|
GH Research PLC
Develops mebufotenin-based therapies for psychiatric and ne…
|
GHRS | IE | Professional, scientific and te… |
|
GI Innovation Inc.
Researches and develops protein-based drugs for immuno-onco…
|
358570 | KR | Professional, scientific and te… |
|
Ginkgo Bioworks Holdings, Inc.
Operates a horizontal platform for cell programming and syn…
|
DNA | US | Professional, scientific and te… |
|
GRAIL, Inc.
A healthcare company developing blood tests for multi-cance…
|
GRAL | US | Professional, scientific and te… |
|
GT Biopharma, Inc.
Clinical-stage immuno-oncology company developing therapies…
|
GTBP | US | Professional, scientific and te… |
|
Guard Therapeutics International AB
Clinical-stage biotech developing therapies to prevent acut…
|
GUARD | SE | Professional, scientific and te… |
|
Gubra A/S
Biotech and CRO focused on peptide drugs for metabolic and …
|
GUBRA | DK | Professional, scientific and te… |
Vimta Labs Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61730/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61730 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61730 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61730 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61730}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Vimta Labs Ltd. (id: 61730)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.